Transcriptomics technologies

Certa Therapeutics presents positive data from a Phase 2 clinical study highlighting the potential benefit of FT011 as a novel treatment for scleroderma

Retrieved on: 
Wednesday, November 15, 2023
Safety, Therapy, Treatment, University, Aes, Scleroderma, Clutch (eggs), Disease, Clinical trial, Biotechnology, EMA, Patient, Royal Free Hospital, FDA, American College of Rheumatology, American College, University College London, RSS, Transcriptomics technologies, MD, Quality of life, ACR, Inflammation, Fibrosis, Pharmaceutical industry, Atlit, Rheumatology

The study safety profile demonstrated that FT011 was safe and well tolerated, with no differences in adverse event (AE) rates between the treatment arms.

Key Points: 
  • The study safety profile demonstrated that FT011 was safe and well tolerated, with no differences in adverse event (AE) rates between the treatment arms.
  • There were no serious AEs reported in the study, nor any AEs resulting in study drug interruption, withdrawal or discontinuation.
  • This suggests that FT011 may have a positive effect for scleroderma patients by reducing the inflammation and fibrosis associated with the disease.
  • It is important to advance safe and effective treatments through clinical development, given the limited therapeutic options for scleroderma patients.

CENTOGENE Expands Multiomic Diagnostic Portfolio With Newly-Launched Transcriptomic Offering

Retrieved on: 
Tuesday, October 10, 2023
Diagnosis, Gene expression, Medicine, Physician, RNA, Cell, DNA, Genomics, Transcriptomics technologies, Artificial intelligence, Neurodegenerative disease, Mox, Tissue, DSM-IV codes, Enzyme, Patient, Vaccine, Medical device

and ROSTOCK, Germany and BERLIN, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the expansion of MOx, the Company’s multiomic diagnostic portfolio, now incorporating cutting-edge transcriptomic analysis.

Key Points: 
  • and ROSTOCK, Germany and BERLIN, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the expansion of MOx, the Company’s multiomic diagnostic portfolio, now incorporating cutting-edge transcriptomic analysis.
  • CENTOGENE’s MOx 2.0 is a single-step multiomic solution that combines DNA sequencing, biochemical testing, and now RNA sequencing to provide physicians with the most comprehensive testing capability.
  • Using RNA sequencing, a more complete picture of disease biology and response to drugs can be established.
  • “Rare and neurodegenerative diseases often present complex diagnostic challenges, requiring a deeper understanding of the genetic and molecular factors at play,” said Prof. Peter Bauer, Chief Medical & Genomic Officer at CENTOGENE.

2023 Annual Single Cell-Omics Conference: Breaking Barriers in Biomedical Research - Explore Single-Cell Omics Innovations (London, United Kingdom - October 9-10, 2023) - ResearchAndMarkets.com

Retrieved on: 
Monday, July 24, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, Drug discovery, University, Knowledge, Diagnosis, Proteomics, Omics, Transcriptomics technologies, Mutation, Protein, Research, Conference, RNA, Genomics, Vaccine

The "2nd Annual Single Cell-Omics Conference" conference has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "2nd Annual Single Cell-Omics Conference" conference has been added to ResearchAndMarkets.com's offering.
  • The conference will assimilate diverse sessions on a broad perspective of novel research and development in the field of multi-omics research.
  • The fundamentals of Single Cell have proven to be an indispensable resource in the sphere of medical research and new diagnostic strategies.
  • Thus, these single cell omics prospects are much anticipated to revolutionise our adequacy to understand the magnitude of omics diversity occurring in our biological systems.

Transgene - Preclinical Results Showing TG6050, a Novel Oncolytic Virus, induces Tumor Regression by Activating Innate and Adaptive immune responses presented at AACR

Retrieved on: 
Monday, April 17, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Human, AACR, Neoplasm, Cancer, American Association for Cancer Research, Phases of clinical research, NSCLC, Lung cancer, Euronext Paris, Patient, Poster, Transcriptomics technologies, Vaccine, Medical imaging

These data demonstrate the ability of TG6050 to induce strong antitumor responses through the production of IL-12 and anti-CTLA4 antibody in the tumor and the induction of innate and adaptive immune responses.

Key Points: 
  • These data demonstrate the ability of TG6050 to induce strong antitumor responses through the production of IL-12 and anti-CTLA4 antibody in the tumor and the induction of innate and adaptive immune responses.
  • TG6050 is a clinical-stage oncolytic virus that has been engineered to encode human IL-12 and a full length anti-CTLA4 antibody.
  • ✓ Transcriptomic and immunological analyses clearly show a remodeling of the tumor micro-environment and the activation of numerous innate and adaptive immune pathways.
  • Hedi Ben Brahim, Transgene’s CEO said, “We have designed TG6050, a novel oncolytic virus encoding the IL-12 and an anti-CTLA4, to generate both innate and adaptive immune responses.

Global RNA Analysis Market Report 2022: Single Cell Transcriptomics And Associated Big Data Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Monday, November 7, 2022
Biotechnology, Genetics, Health, MicroRNA, RNA, Research, PCR, NGS, CD Genomics, Investment, Element, RNA transfection, Biotechnology, CAGR, Industry, Asia-Pacific, Biomarker, Application, Digital, Data management, COVID-19, Clifton Springs Hospital & Clinic, Cros, Transcriptomics technologies, Transcriptome, USFDA, USD, Drug development, Sequencing, Kits, Real-time, Union, Genomics, Gene, Patient, Hospital, Fine chemical, Pharmaceutical industry, Technology, Instrument

The global RNA analysis market size is anticipated to reach USD 42.30 billion by 2030, expanding at a CAGR of 16.59% from 2022 to 2030.

Key Points: 
  • The global RNA analysis market size is anticipated to reach USD 42.30 billion by 2030, expanding at a CAGR of 16.59% from 2022 to 2030.
  • Technological advancements in this industry can be attributed to the increasing applications of transcriptome sequencing in life science for capturing polyadenylated RNA.
  • With the expansion of next-generation high-throughput sequencing technology, the analysis of transcriptomes has been gradually improving the understanding of the regulatory network of RNA-based genes.
  • For instance, in July 2021, the Lithuanian team is developing a droplet-based technique for simultaneous mRNA and microRNA capture and sequencing in a single cell.

Spatial Genomics and Transcriptomics Global Market Report 2022: Growing Research and Development in Healthcare and Pharmaceutical Industry Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 4, 2022
General Health, Science, Health, Research, Transcriptomics technologies, Row, CAGR, Porter's five forces analysis, Medicinal plants

The "Spatial Genomics and Transcriptomics Market : Global Industry Analysis, Trends, Market Size, and Forecasts up to 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Spatial Genomics and Transcriptomics Market : Global Industry Analysis, Trends, Market Size, and Forecasts up to 2028" report has been added to ResearchAndMarkets.com's offering.
  • The report on the global spatial genomics and transcriptomics market provides qualitative and quantitative analysis for the period from 2020 to 2028.
  • The report predicts the global spatial genomics and transcriptomics market to grow with a CAGR of nearly 17% over the forecast period from 2022-2028.
  • The report on spatial genomics and transcriptomics market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global spatial genomics and transcriptomics market over the period of 2020 to 2028.

Africa Spatial Genomics and Transcriptomics Market Report 2022: Prospects, Trends Analysis, Size & Forecasts to 2027 - ResearchAndMarkets.com

Retrieved on: 
Monday, September 12, 2022
Health, General Health, Transcriptomics technologies, Retail

The "Africa Spatial Genomics and Transcriptomics Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Africa Spatial Genomics and Transcriptomics Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2027" report has been added to ResearchAndMarkets.com's offering.
  • The country research report on Africa spatial genomics and transcriptomics market is a customer intelligence and competitive study of the Africa market.
  • Moreover, the report provides deep insights into demand forecasts, market trends, and, micro and macro indicators in the Africa market.
  • The report on Africa spatial genomics and transcriptomics market provides a detailed analysis of segments in the market based on technique, product, application, and end-user.

Instil Bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Friday, August 12, 2022
FDA, ASCO, Cell, GLOBE, American Society of Clinical Oncology, Cervical cancer, CA, TIL, Cancer, Sale, FOLR1, European Medicines Agency, Society, Renal cell carcinoma, Transcriptomics technologies, NSCLC, Gene, Pembrolizumab, Single cell sequencing, Neck, Company, Large-cell lung carcinoma, Costar, Tumor microenvironment, NASDAQ, RCC, TILS, Research, BLA, European Society of Gene and Cell Therapy, Head, Melanoma, Ovarian cancer, US Foods, Food, MAA, Photo-induced cross-linking of unmodified proteins, Pharmaceutical industry, Vaccine, Medical imaging, DALLAS, Patient

DALLAS, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today reported its second quarter 2022 financial results and provided a corporate update.

Key Points: 
  • Enrolling Phase 1 study of ITIL-306, Instils first CoStAR-TIL: Instil has initiated a Phase 1 study of ITIL-306, its first CoStAR-TIL product candidate.
  • CoStAR is a genetic modification designed to enhance the activity of TILs within the tumor microenvironment.
  • Title: Characterization of the Transcriptomic and TCR Clonal Heterogeneity of TIL Therapy Infusion Products by Single-Cell Sequencing and Correlative Analyses With Clinical Efficacy in Patients with Advanced Cutaneous Melanoma.
  • General and administrative expenses were $17.2 million and $32.3 million for the three and six months ended June30, 2022, respectively, compared to $14.2 million and $23.2 million for the three and six months ended June30, 2021, respectively.

Outlook on the Bioinformatics Global Market to 2027 - Blockchain Technology and Cloud Computing Present Opportunities - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 19, 2022
Biotechnology, Biometrics, Health, Pharmaceutical, Health Technology, Knowledge, Drug discovery, Porter's five forces analysis, Investment, CAGR, Product, Ansoff Matrix, Observation, Industry, SWOT, Geography, Transcriptomics technologies, Risk, Growth, Emotion, Impact, Ortho Clinical Diagnostics, USD, Personalized medicine, Co-production (public services), COVID-19, Market development, Competitive analysis, Retail, Risk management, Pharmaceutical industry, Marketing, Medical device, Proteomics, Genomics, Metabolomics

The Global Bioinformatics Market is estimated to be USD 12.28 Bn in 2022 and is projected to reach USD 24.85 Bn by 2027, growing at a CAGR of 15.14%.

Key Points: 
  • The Global Bioinformatics Market is estimated to be USD 12.28 Bn in 2022 and is projected to reach USD 24.85 Bn by 2027, growing at a CAGR of 15.14%.
  • Market dynamics are forces that impact the prices and behaviors of the Global Bioinformatics Market stakeholders.
  • The report analyses the Global Bioinformatics Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
  • Growing Applications of Bioinformatics in Proteomics and Drug Discovery, Clinical Diagnostics and Personalized Medicine
    The Global Bioinformatics Market is segmented based on Bioinformatics Platform, Applications, End-User and Geography.

The Worldwide Transcriptomics Industry is Expected to Reach $9.4 Billion by 2027 - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 30, 2022
Health, Genetics, Diagnosis, A-DNA, National, Biotechnology, Biology, Research, Technology, Real-time polymerase chain reaction, Gene, Lists of diseases, Biomarker, Transcriptome, SAGE, Growth, Gene expression, Application, Cancer, Industry, Tuberculosis, Method, NIH, Bias, CAGR, Personalized medicine, Drug discovery, Toxicity, RNA, Polymerase chain reaction, Cardiovascular disease, DNA, Reverse transcriptase, National Human Genome Research Institute, PCR, Component, Vaccine, Government, EST, Knowledge, Transcriptomics technologies, RNA interference, Medical imaging, Pharmaceutical industry

The Global Transcriptomics Market size is expected to reach $9.4 billion by 2027, rising at a market growth of 7.6% CAGR during the forecast period.

Key Points: 
  • The Global Transcriptomics Market size is expected to reach $9.4 billion by 2027, rising at a market growth of 7.6% CAGR during the forecast period.
  • Quantitative reverse transcription, or q PCR, is a technique for detecting the presence and quantity of RNA by turning it into cDNA.
  • It is named reverse transcription since it is carried out with the help of a polymerase chain reaction.
  • In addition, transcriptomics data from RNA sequencing has low genome coverage and strong amplification bias, making data interpretation difficult, particularly without effective bioinformatics tools.